AI assistant
Sending…
Jazz Pharmaceuticals plc — Director's Dealing 2026
Jan 21, 2026
30751_dirs_2026-01-21_5e2e849a-e076-421d-980e-031721a6874d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2026-01-16
Reporting Person: COZADD BRUCE C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-16 | Ordinary Shares | A | 35917 | $0.0 | Acquired | 429249 | Direct |
| 2026-01-16 | Ordinary Shares | F | 17453 | $171.16 | Disposed | 411796 | Direct |
Footnotes
F1: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance
attained was certified.
F2: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.
More from Jazz Pharmaceuticals plc
Regulatory Filings
2026
May 29
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2